- 2024.5.10IRFinancial Results for the Fiscal Year ended March 31, 2024 [Japanese GAAP] (non-consolidated)(507KB)
- 2024.3.4IRTopline Results of Phase I Clinical Trial of iPS-NKT in Patients with Relapsed or Refractory Head and Neck Cancer(186KB)
- 2024.2.21PRCollaborative researcher will be presenting at CD1-MR1 2024
- 2024.2.9IRFinancial Results for the Nine Months ended December 31, 2023 [Japanese GAAP] (non-consolidated)(302KB)
- 2024.5.10IRFinancial Results for the Fiscal Year ended March 31, 2024 [Japanese GAAP] (non-consolidated)(507KB)
- 2024.3.4IRTopline Results of Phase I Clinical Trial of iPS-NKT in Patients with Relapsed or Refractory Head and Neck Cancer(186KB)
- 2024.2.9IRFinancial Results for the Nine Months ended December 31, 2023 [Japanese GAAP] (non-consolidated)(302KB)